Clinical trials: Attention Disorder With Hyperactivity (ADHD)
- Condition Attention Disorder With Hyperactivity (ADHD)
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder
CX717 in the Treatment of Adult ADHD
A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder
- Trial name
- NCT03375021
- Testing
- CX717 200 mg, CX717 800 mg
- Volunteers
- 68 people
- Sponsor
- RespireRx
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD
The purpose of this trial is to test the effectiveness of atomoxetine in treating symptoms of ODD in children with ADHD and ODD.
- Trial name
- NCT00191698
- Testing
- atomoxetine hydrochloride
- Where
- 16 sites in Australia, Belgium and 6 more
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder
This study will determine whether the drug betahistine increases focus and causes side effects in people with attention deficit hyperactivity disorder.
- Trial name
- NCT00829881
- Testing
- Betahistine Hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- P2D, Inc.
Adult Attention Deficit Hyperactivity Disorder
Dasotraline Adult ADHD Study
This is a randomized, double blind, multicenter, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in adults with ADHD.
- Trial name
- NCT02276209
- Testing
- Dasotraline
- Where
- 59 sites in United States
- Volunteers
- 636 people
- Sponsor
- Sumitomo Pharma America, Inc.
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of high doses of SPN-812 in adolescents (12-17 years old) with ADHD
- Trial name
- NCT03247556
- Testing
- 400mg SPN-812, 600mg SPN-812
- Where
- 14 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.
2-week open-label safety, tolerability and pharmacokinetic study of methylphenidate HCl ERCT in 4-5 year old children with ADHD.
- Trial name
- NCT03546400
- Testing
- methylphenidate HCl ERCT
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
This study was designed to compare Concerta Extended Release tablets with Metadate CD capsules in children with ADHD who were between 6 and 12 years old.
- Trial name
- NCT00381758
- Testing
- Methylphenidate Extended Release Capsules
- Volunteers
- 184 people
- Sponsor
- UCB Pharma
ADHD, Attention Deficit Hyperactivity Disorder
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined
- Trial name
- NCT05286762
- Testing
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cingulate Therapeutics
Attention-Deficit/Hyperactivity Disorder
Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
The purpose of this study is to assess whether changes in the symptoms of ADHD show a relationship with changes in functioning in children with ADHD treated with atomoxetine over a 3-month period.
- Trial name
- NCT00191633
- Testing
- Atomoxetine
- Where
- 19 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Assessing Mobile Apps for Adult ADHD
The purpose of this clinical trial is to evaluate the effects of mobile app digital therapies on cognitive function and symptoms in adults diagnosed with ADHD.
- Trial name
- NCT06256003
- Testing
- UC-A, UC-N
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Think Now Incorporated
Attention Deficit Hyperactivity Disorder
Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
There has been an increased interest in the association between ADHD and sleep disorders over the past years. A high incidence of sleep disturbance, ranging from 10% to 70%, has been identified in ADHD children regardless of…
- Trial name
- Zolkids (NCT00318448)
- Testing
- Zolpidem (SL800750)
- Where
- 2 sites in United States, Canada
- Volunteers
- 201 people
- Sponsor
- Sanofi
Attention-Deficit/Hyperactivity Disorder
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
- Trial name
- NCT06185985
- Testing
- SPN-812
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.
- Trial name
- NCT00626236
- Testing
- SPN-810
- Where
- 9 sites in United States
- Volunteers
- 78 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Attention Deficit Hyperactivity Disorder (ADHD)
The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD
ADHD is the most frequent neurodevelopmental disorder in childhood. Symptoms often appear in preschool years, and most children (65-80%) continue to experience some ADHD-associated symptoms into adolescence and adulthood.
- Trial name
- NCT06542445
- Testing
- Oral CBD oil enriched with terpenes
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Bazelet Nehushtan LtD.
ADHD
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).
- Trial name
- NCT00764868
- Testing
- Lisdexamfetamine Dimesylate (LDX)
- Where
- 45 sites in United States
- Volunteers
- 269 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in…
- Trial name
- NCT00723190
- Testing
- CLONICEL (Clonidine HCl sustained release)
- Where
- 27 sites in United States
- Volunteers
- 303 people
- Sponsor
- Shionogi
ADHD
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.
- Trial name
- NCT00141063
- Testing
- Focalin XR
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Novartis